Agilent Technologies Inc. (NYSE: A) today introduced two new assays for the 2200 TapeStation system: the
RNA ScreenTape and the D1000 ScreenTape assays
. Both assays are essential for the quality control of samples in next-generation sequencing (NGS) workflow. They replace Agilent’s R6K and D1K ScreenTape assays.
The new RNA ScreenTape assay delivers qualitative and quantitative assessment of total RNA for both eukaryotic and prokaryotic samples, with a Bioanalyzer-like electropherogram and RNA Integrity Number equivalent (RIN
) quality score. The new D1000 ScreenTape assay builds on the success of the D1K ScreenTape, with closer alignment in sizing and quantification to the market-leading
2100 Bioanalyzer system
“Next-generation sequencing has become an invaluable tool for life science researchers, and the key to achieving the highest-quality NGS results is the ability to monitor and ensure the quality of samples being prepared throughout the front-end process,” said Yvonne Linney, vice president and general manager of Agilent’s Life Science Solutions Division. “The
2200 TapeStation system
is an ideal technology for this, providing a simplified, automated process for nucleic acid quality control. With enhanced performance, these new assays optimize quantification and sizing and improve RNA resolution.”
For more information about the new Agilent RNA ScreenTape and D1000 ScreenTape assays visit
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement company. The separation is expected to be completed in early November 2014.